Profil
Gordon McInroy has founded Nuclera Nucleics Ltd.
in 2013 and currently holds the position of Director & Chief Technology Officer.
Postes actifs de Gordon McInroy
| Sociétés | Poste | Début |
|---|---|---|
Nuclera Nucleics Ltd.
 Nuclera Nucleics Ltd. BiotechnologyHealth Technology Nuclera Nucleics Ltd. is a British company that specializes in making biology accessible through desktop enzymatic protein and gene synthesis. The company was founded in 2013 by four PhD students at the University of Cambridge who were frustrated by the inaccessibility of biology. Nuclera has since grown to fifty-seven employees across two continents and is headquartered in Cambridge, UK. The company's vision is to make biology accessible to everyone through desktop bioprinting, which empowers researchers and scientists to take control of biology through streamlined access to a next-day supply of proteins and genes. Nuclera's desktop bioprinter is enabled by three exciting technologies protected by 45+ patents: enzymatic protein synthesis, enzymatic gene synthesis, and digital microfluidics. The combination of these technologies in a deployable desktop bioprinting platform creates an unprecedented one-stop-shop ecosystem that enables Nuclera to provide consistent biological workflows, products, and information to its customers. Michael Chen has been the CEO since 2013. | Fondateur | 01/01/2013 |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 1 |
|---|---|
Nuclera Nucleics Ltd.
Nuclera Nucleics Ltd. BiotechnologyHealth Technology Nuclera Nucleics Ltd. is a British company that specializes in making biology accessible through desktop enzymatic protein and gene synthesis. The company was founded in 2013 by four PhD students at the University of Cambridge who were frustrated by the inaccessibility of biology. Nuclera has since grown to fifty-seven employees across two continents and is headquartered in Cambridge, UK. The company's vision is to make biology accessible to everyone through desktop bioprinting, which empowers researchers and scientists to take control of biology through streamlined access to a next-day supply of proteins and genes. Nuclera's desktop bioprinter is enabled by three exciting technologies protected by 45+ patents: enzymatic protein synthesis, enzymatic gene synthesis, and digital microfluidics. The combination of these technologies in a deployable desktop bioprinting platform creates an unprecedented one-stop-shop ecosystem that enables Nuclera to provide consistent biological workflows, products, and information to its customers. Michael Chen has been the CEO since 2013. | Health Technology |
